Following multiple surgeries, years of chronic pain, trauma-related symptoms and a growing collection of prescription bottles, I found myself asking a question I never expected to ask: Why are we so quick to trust a pill but so slow to trust a plant?

As a veteran, I’ve spent years navigating the healthcare system. I’ve dealt with chronic pain, sleep disturbances, alcohol recovery and the challenges that come with trying to improve quality of life while managing an ever-growing list of medical conditions. Throughout that journey, I noticed a pattern. When a physician prescribed another medication, few people questioned it. When cannabis entered the conversation, however, the reaction was often skepticism, concern or outright dismissal.

That disconnect made me curious.

Not about whether cannabis was a miracle cure. It isn’t.

Not about whether modern medicine works. It does.

But about why certain treatment options are readily accepted while others continue to carry a stigma despite growing scientific evidence and widespread public use.

For much of the last century, Americans were taught that cannabis was dangerous, addictive and devoid of legitimate medical value. Schools taught it. Public service campaigns reinforced it. Popular culture repeated it. Over time, those messages became deeply embedded in public consciousness.

At the same time, medications that arrived through traditional healthcare channels were generally viewed as legitimate by default. If a treatment came from a doctor, a pharmacy or a major healthcare institution, most people assumed it had earned its place in medicine.

Then reality became more complicated.

Millions of Americans began having direct or secondhand experiences that challenged the old narrative. They watched cancer patients use cannabis to combat nausea and restore appetite. They saw chronic pain sufferers reduce their reliance on opioids. They met veterans struggling with trauma-related symptoms who reported improvements in sleep and overall quality of life. They watched older adults turn to cannabis products after finding limited relief from conventional treatments.

I became one of those people.

Following major surgeries and years of chronic pain, I experienced the cycle many patients know all too well: one medication to treat a condition, another to manage side effects and still another to address new symptoms that emerged along the way. While many of those medications served an important purpose, I found myself wondering whether patients were being encouraged to consider all available options or only the options that fit comfortably within the existing healthcare framework.

Scientific research has increasingly supported a more nuanced conversation.

In 2017, the National Academies of Sciences, Engineering and Medicine concluded that substantial evidence supports cannabis or cannabinoid use for chronic pain in adults, chemotherapy-induced nausea and vomiting, and symptoms associated with multiple sclerosis.

Today, medical cannabis programs operate in more than three dozen states, and millions of Americans have legally accessed cannabis for medical purposes.

The real question is whether cannabis is being evaluated according to the same standards applied to other therapeutic options.

At the same time, public trust in institutions has been changing. Surveys conducted by Gallup and Pew Research Center have documented declining confidence in many major American institutions. More Americans are questioning established narratives and seeking information independently.

The opioid epidemic further complicated public perceptions of medical authority. While prescription opioids remain essential medications for many patients, the crisis demonstrated that treatments once considered unquestionably safe could carry serious consequences when overprescribed or improperly managed.

According to Gallup, support for cannabis legalization has risen from roughly 12% in 1969 to approximately 70% today. Younger generations are increasingly evaluating cannabis through a comparative-risk lens rather than through decades-old stereotypes.

As someone who has personally struggled with alcohol in the past, I find this shift particularly interesting. Younger adults appear increasingly willing to question why alcohol enjoys widespread cultural acceptance while cannabis remains burdened by lingering stigma.

The debate over cannabis is no longer simply a debate about cannabis.

It is a debate about whether patients deserve access to all credible evidence.

It is a debate about whether science should outweigh stigma.

It is a debate about whether individuals can be trusted to participate in decisions about their own health.

Patients deserve honest information, meaningful choices and the opportunity to consider every reasonable treatment option. They should be encouraged to explore all credible scientific evidence, including information that may receive less attention in traditional healthcare discussions or mainstream media coverage.

Cannabis may not be the right choice for every patient. Neither are some prescription medications. But if we truly believe in evidence-based medicine, then every treatment option deserves to be evaluated fairly, openly and according to the same standards.

The future of healthcare should not be built on assumptions. It should be built on evidence, transparency and informed patient choice. And that begins with an open mind.

Christopher Daw is an Alaska veteran, father and advocate for informed patient choice in healthcare. Drawing from personal experience with chronic pain, trauma recovery, alcohol recovery and long-term interaction with the healthcare system, he writes about healthcare policy, patient autonomy and evidence-based approaches to wellness.

• • •

The Anchorage Daily News welcomes a broad range of viewpoints. To submit a piece for consideration, email commentary(at)adn.com. Send submissions shorter than 200 words to letters@adn.com or click here to submit via any web browser. Read our full guidelines for letters and commentaries here.